Drug developers integrate AI capabilities as a potentially transformative strategy to combat patent cliff losses.

Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.

Márcio Temtem, Hovione, discusses how to tackle pharma complexity via regional growth in the US, Ireland, and Portugal, using digital tools to accelerate development.

Define Ventures’ new report provides a clear framework for how enterprise healthcare, particularly Big Pharma, is transitioning from AI exploration to execution. It focuses on core categories, ...

We've entered the era of the "frontier firm"—an organization where artificial intelligence (AI) isn't just a tool but the ...

Introducing Pharmony At this critical time, the PM Society is launching Pharmony, a positive, evidence-led response to counter the negativity and uncertainty that dominates. It’s an initiative that ...

As advances in artificial intelligence technology continue to offer enticing benefits to industries across the board, pharma leaders aren't looking to miss out on implementing the technology into ...

Márcio Temtem, Hovione, discusses how his company integrates modular hardware and modeling software to accelerate pharmaceutical R&D and optimize manufacturing processes.

Halozyme Therapeutics has been busy. While fighting a patent dispute with Merck & Co. and navigating the impact of the Inflation Reduction Act (IRA), the company has penned an acquisition of fellow ...

The pharmaceutical industry invests billions of dollars 1 in digital tools and technologies. But for all the online surveys, feedback loops, and digital portals introduced to improve the patient ...